ChemoCentryx Stock News

MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two up

MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market clos

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This article will reflect on the compensation paid to Thomas Schall who has served as CEO of ChemoCentryx, Inc...

Largest insider trades of the week Continue reading...

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin

Exane Derivatives decreased its holdings in ChemoCentryx Inc (NASDAQ:CCXI) by 24.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange C

Largest insider trades of the week Continue reading...

MOUNTAIN VIEW, Calif., July 09, 2020 -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug.

Stocks Analysis by Investing Insights covering: ChemoCentryx Inc, United Therapeutics Corporation, Axsome Therapeutics Inc. Read Investing Insights 's latest article on Investing.com

Disconnected. This seems to be the best way to describe the current economic environment. Amid high levels of unemployment and tanking earnings, stocks aren’t just hanging in there, they’re chargi

Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.

Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a sh

ChemoCentryx Inc (NASDAQ:CCXI) has received a consensus recommendation of “Buy” from the twelve ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock wit

Geode Capital Management LLC grew its position in ChemoCentryx Inc (NASDAQ:CCXI) by 10.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).